Table 4 Clinical and therapeutic characteristics
P ovale curtisi (n=35) | P ovale wallikeri (n=44) | p | |
|---|---|---|---|
Asymptomatic | 2 (5.7) | 2 (4.5) | 1 |
Fever | 32 (91.4) | 39 (88.6) | 1 |
Headache | 17 (48.6) | 29 (65.9) | 0.121 |
Nausea | 9 (25.7) | 11 (25.0) | 0.942 |
Arthralgia | 10 (28.6) | 15 (34.1) | 0.600 |
Myalgia | 17 (48.6) | 18 (40.9) | 0.496 |
Vomitus | 4 (11.4) | 12 (26.3) | 0.082 |
Abdominal pain | 5 (14.3) | 3 (6.8) | 0.460 |
Diarrhea | 4 (11.4) | 5 (11.4) | 1 |
Other (cough, dyspnea, chest pain, dizziness) | 9 (25.7) | 10 (22.7) | 0.758 |
Duration of hospitalization, median days (IQR) | 4 (2.0–6.0) | 3 (3.0–6.0) | 0.713 |
Treatment | 0.826 | ||
Chloroquine | 17 (48.6) | 18 (40.9) | |
Atovaquone/proguanil | 12 (34.2) | 11 (25.0) | |
Quinine + doxycycline | 2 (4.5) | ||
Atovaquone/proguanil + chloroquine | 1 (2.9) | 1 (2.3) | |
Artesunate + artemether–lumefantrine | 1 (2.9) | ||
Dihidroartemisinin–piperaquine | 3 (8.6) | 7 (15.9) | |
Artemether–lumefantrine | 1 (2.3) | ||
Artesunate + chloroquine | 1 (2.3) | ||
Artesunate + atovaquone/proguanil | 1 (2.9) | ||
Artesunate | 1 (2.3) | ||
Lost to follow up, no treatment | 2 (4.5) | ||
Primaquine | 25 (71.4) | 34 (81.0) | 0.325 |
Severe malaria and complications | 1 | ||
Total bilirubin > 3 mg/dL and haemoglobin < 7 g/dL | 1 (2.9)a | ||
Total bilirubin > 3 mg/dL | 3 (6.8)b | ||
Haemoglobin < 7 g/dL | 1 (2.9) | ||
Haemophagocytosis | 1 (2.3) | ||
Exitus | 0 | 0 | 1 |